Thus, our data, derived from multiplex assays and the observation of PDGF over-expression and STAT3 activation in evolved tumors, validates the concept of using crizotinib or ruxolitinib as a third agent in combination with [pazopanib + AR42] to enhance tumor cell killing and to circumvent the development of drug resistance. This evidence concerns the gene STAT3 and neoplasm.